Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or 'the Company', HKEX: 6990) today announced that its partner, Windward Bio AG ('Windward Bio') has launched its Phase 2 POLARIS ...

Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 HBM9378/WIN378 has the potential to be ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

A digital asthma self-management program enhanced symptom control; however, it revealed racial disparities in engagement, highlighting the need for culturally tailored interventions.

In a wholly new approach to cancer treatment, Northwestern University biomedical engineers have doubled the effectiveness of ...